NGM Stock Crashes As NASH Drug Joins Gilead, Genfit With Notable Flops

NGM Biopharmaceuticals (NGM) joined a raft of biotech companies with a failed hepatitis treatment on Monday, leading NGM stock to crash.


The biotech company was working on a treatment for non-alcoholic steatohepatitis, or NASH, an aggressive form of fatty liver disease. But the drug failed to improve fibrosis by at least one stage while keeping NASH symptoms in check. That was the primary goal of the study.

In morning trading on the stock market today, NGM stock collapsed 42.1% near 16.40. Now, the company says it will focus on its portfolio of drugs for eye disease and cancer. NGM said it won’t send the experimental NASH treatment into later-stage testing.

“These results are certainly disappointing, particularly given the dire unmet need in this patient population,” Chief Executive David Woodhouse said in a written statement. “The lack of significant fibrosis improvement was unexpected given the consistency of histology findings previously seen with (the drug called) aldafermin in our adaptive four-cohort Phase 2 study.”

NGM Stock Crashes

The news sent NGM stock crashing to its lowest point since September. Shares were consolidating with a buy point at 32.22, according to

But NGM is far from the only name with a NASH failure under its belt. The disease is fairly tricky.

First, patients don’t show symptoms until their livers become extensively scarred and develop cirrhosis. Then, it can’t actually be diagnosed without an invasive liver biopsy. And, in order to gain U.S. approval, a drug must either improve fibrosis and keep NASH symptoms in check, or it must resolve NASH entirely and prevent fibrosis from worsening.

The field is riddled with failures from high-profile names like Gilead Sciences (GILD) and Genfit (GNFT). In June 2020, the FDA rejected Intercept Pharmaceuticals’ drug.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


The Fight Against Alzheimer’s Reaches A Moment Of Truth For Biogen, Other Biotech Stocks

Annovis Bio Stock Doubles As Alzheimer’s Drug Tops Biogen, Cassava Sciences

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Short-Term Trades Can Add Up To Big Profits. IBD’s SwingTrader Shows You How

Want More IBD Insights? Subscribe To Our Investing Podcast!

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button